Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Rabies vaccine (Primary)
- Indications Rabies
- Focus Pharmacodynamics
- Sponsors Novartis
- 13 Dec 2011 Actual patient number (630) added as reported by ClinicalTrials.gov.
- 13 Dec 2011 Novartis Vaccines added as trial affiliate as reported by ClinicalTrials.gov.
- 13 Dec 2011 Primary endpoint identified as 'clinical response' as reported by ClinicalTrials.gov.